Clinical Trial Update: A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating autologous natural killer (NK) cells in combination with a GD2-targeted monoclonal antibody for newly diagnosed high-risk …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• autologous NK cell therapy (autologous natural killer cells)
• dinutuximab (dinutuximab)

Snippet

Sponsor: Guangzhou Women and Children's Medical Center | Conditions: Neuroblastoma, GD2 Antibody | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING